Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Gossamer Bio ( (GOSS) ) has provided an announcement.
On June 25, 2025, Gossamer Bio held its annual stockholders meeting where key decisions were made, including the approval of the Amended and Restated 2019 Incentive Award Plan. Additionally, the meeting saw the re-election of three Class I directors, the ratification of Ernst & Young LLP as the independent accounting firm for 2025, and an advisory approval of executive compensation, reflecting strategic governance and operational decisions that could impact the company’s future direction.
The most recent analyst rating on (GOSS) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Gossamer Bio stock, see the GOSS Stock Forecast page.
Spark’s Take on GOSS Stock
According to Spark, TipRanks’ AI Analyst, GOSS is a Underperform.
The overall stock score for Gossamer Bio is low, primarily due to significant financial challenges, including high leverage and consistent losses. While there is some improvement in revenue and cash flow, the company remains unprofitable. Technical analysis suggests market uncertainty, and valuation metrics show limited attractiveness due to a negative P/E ratio and no dividend yield.
To see Spark’s full report on GOSS stock, click here.
More about Gossamer Bio
Gossamer Bio, Inc. operates in the biotechnology industry, focusing on the development and commercialization of innovative therapeutics for the treatment of various diseases.
Average Trading Volume: 1,545,969
Technical Sentiment Signal: Buy
Current Market Cap: $311.4M
For detailed information about GOSS stock, go to TipRanks’ Stock Analysis page.